BR0114689A - Composto, composição farmacêutica, processo para a produção de uma composição farmacêutica, métodos para eliciar um efeito de modulação de receptor de estrogênio em um mamìfero, para o tratamento ou prevenção de, osteporose, pósmenopausa em um indivìduo do sexo feminino, e para o tratamento ou prevenção de um distúrbio - Google Patents

Composto, composição farmacêutica, processo para a produção de uma composição farmacêutica, métodos para eliciar um efeito de modulação de receptor de estrogênio em um mamìfero, para o tratamento ou prevenção de, osteporose, pósmenopausa em um indivìduo do sexo feminino, e para o tratamento ou prevenção de um distúrbio

Info

Publication number
BR0114689A
BR0114689A BR0114689-0A BR0114689A BR0114689A BR 0114689 A BR0114689 A BR 0114689A BR 0114689 A BR0114689 A BR 0114689A BR 0114689 A BR0114689 A BR 0114689A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
female
prevention
treatment
estrogen receptor
Prior art date
Application number
BR0114689-0A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BR0114689A publication Critical patent/BR0114689A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D327/00Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06Six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D339/00Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/08Six-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, PROCESSO PARA A PRODUçãO DE UMA COMPOSIçãO FARMACêUTICA, MéTODOS PARA ELICIAR UM EFEITO DE MODULAçãO DE RECEPTOR DE ESTROGêNIO EM UM MAMìFERO, PARA O TRATAMENTO OU PREVENçãO DE OSTEPOROSE PóS-MENOPAUSA EM UM INDIVìDUO DO SEXO FEMININO, E PARA O TRATAMENTO OU PREVENçãO DE UM DISTúRBIO". A presente invenção refere-se a compostos e derivados dos mesmos, à sua síntese, e a seu uso como moduladores de receptor de estrogênio. Os compostos da presente invenção são ligantes para receptores de estrogênio e como tais podem ser úteis para o tratamento ou a prevenção de uma variedade de condições relacionadas ao funcionamento de estrogênio incluindo: perda óssea, fraturas ósseas, osteoporose, degeneração de cartilagem, endometriose, doença fibróide uterina, queimações, níveis aumentados de LD1, colesterol, doença cardiovascular, dano do funcionamento cognitivo, distúrbios degenerativos cerebrais, restenose, ginecomastia, proliferação da célula do músculo liso vascular, obesidade, incontinência, e câncer, em particular da mama, útero e próstata.
BR0114689-0A 2000-10-19 2001-10-15 Composto, composição farmacêutica, processo para a produção de uma composição farmacêutica, métodos para eliciar um efeito de modulação de receptor de estrogênio em um mamìfero, para o tratamento ou prevenção de, osteporose, pósmenopausa em um indivìduo do sexo feminino, e para o tratamento ou prevenção de um distúrbio BR0114689A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24158200P 2000-10-19 2000-10-19
PCT/US2001/042735 WO2002032377A2 (en) 2000-10-19 2001-10-15 Estrogen receptor modulators

Publications (1)

Publication Number Publication Date
BR0114689A true BR0114689A (pt) 2003-07-01

Family

ID=22911282

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114689-0A BR0114689A (pt) 2000-10-19 2001-10-15 Composto, composição farmacêutica, processo para a produção de uma composição farmacêutica, métodos para eliciar um efeito de modulação de receptor de estrogênio em um mamìfero, para o tratamento ou prevenção de, osteporose, pósmenopausa em um indivìduo do sexo feminino, e para o tratamento ou prevenção de um distúrbio

Country Status (20)

Country Link
EP (1) EP1333827A2 (pt)
JP (1) JP2004511502A (pt)
KR (1) KR20030042020A (pt)
CN (1) CN1469743A (pt)
AU (2) AU2002232381B2 (pt)
BG (1) BG107676A (pt)
BR (1) BR0114689A (pt)
CA (1) CA2424729A1 (pt)
EA (1) EA200300474A1 (pt)
EC (1) ECSP034558A (pt)
EE (1) EE200300153A (pt)
HU (1) HUP0303563A2 (pt)
IL (1) IL154984A0 (pt)
IS (1) IS6761A (pt)
MX (1) MXPA03003485A (pt)
NO (1) NO20031737L (pt)
PE (1) PE20021083A1 (pt)
PL (1) PL361053A1 (pt)
SK (1) SK4772003A3 (pt)
WO (1) WO2002032377A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225132A1 (en) * 2002-04-11 2003-12-04 Dininno Frank P. Estrogen receptor modulators
ES2350446T3 (es) * 2002-04-24 2011-01-24 MERCK SHARP & DOHME CORP. Moduladores de los receptores de estrógenos.
JP4500689B2 (ja) * 2002-12-26 2010-07-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 選択的エストロゲン受容体モジュレーター
AU2006275514B2 (en) * 2005-07-29 2012-04-05 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
WO2007049798A1 (ja) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. 新規ベンゾオキサチイン誘導体
US8053440B2 (en) 2007-02-01 2011-11-08 Resverlogix Corporation Compounds for the prevention and treatment of cardiovascular diseases
EP2382194B1 (en) 2009-01-08 2014-03-12 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
JP5795304B2 (ja) 2009-03-18 2015-10-14 レスバーロジックス コーポレイション 新規抗炎症剤
KR101892987B1 (ko) 2009-04-22 2018-08-30 리스버로직스 코퍼레이션 신규한 소염제
EP2580210B1 (en) 2010-06-10 2017-03-01 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
DK2773354T3 (da) 2011-11-01 2019-08-05 Resverlogix Corp Oralformuleringer med øjeblikkelig frigivelse for substituerede quinazolinoner
US9187460B2 (en) 2011-12-14 2015-11-17 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
KR102662814B1 (ko) 2015-03-13 2024-05-03 리스버로직스 코퍼레이션 보체 관련 질환을 치료하기 위한 조성물 및 치료 방법

Also Published As

Publication number Publication date
PE20021083A1 (es) 2002-12-16
AU2002232381B2 (en) 2004-11-18
HUP0303563A2 (hu) 2004-03-01
CN1469743A (zh) 2004-01-21
PL361053A1 (en) 2004-09-20
MXPA03003485A (es) 2003-07-14
NO20031737L (no) 2003-06-19
IS6761A (is) 2003-03-27
ECSP034558A (es) 2003-06-25
EA200300474A1 (ru) 2003-10-30
WO2002032377A3 (en) 2002-08-22
CA2424729A1 (en) 2002-04-25
EP1333827A2 (en) 2003-08-13
JP2004511502A (ja) 2004-04-15
KR20030042020A (ko) 2003-05-27
EE200300153A (et) 2003-06-16
WO2002032377A2 (en) 2002-04-25
NO20031737D0 (no) 2003-04-15
BG107676A (bg) 2003-11-28
SK4772003A3 (en) 2003-08-05
AU3238102A (en) 2002-04-29
IL154984A0 (en) 2003-10-31

Similar Documents

Publication Publication Date Title
BR0114689A (pt) Composto, composição farmacêutica, processo para a produção de uma composição farmacêutica, métodos para eliciar um efeito de modulação de receptor de estrogênio em um mamìfero, para o tratamento ou prevenção de, osteporose, pósmenopausa em um indivìduo do sexo feminino, e para o tratamento ou prevenção de um distúrbio
ATE524170T1 (de) Östrogenrezeptor modulatoren
DK1501819T3 (da) Østrogenreceptormodulatorer
BRPI0518874A2 (pt) composto, composiÇço farmacÊutica, e, usos de um composto, e de uma composiÇço
WO2002091993A3 (en) Estrogen receptor modulators
BRPI0517224A (pt) composto, composição farmecêutica, e, usos de um composto e de uma composição
DE60120746D1 (de) Östrogenrezeptormodulatoren
Kumar et al. Single locking compression plate fixation of extra-articular distal humeral fractures
Chang et al. Comparison of clavicular hook plate with and without coracoclavicular suture fixation for acute acromioclavicular joint dislocation
WO2004073612A3 (en) Estrogen receptor modulators
WO2006081152A3 (en) Estrogen receptor modulators
Dietz et al. Retrograde nailing versus locking plate osteosynthesis of proximal humeral fractures: a biomechanical study
WO2002032373A3 (en) Estrogen receptor modulators
AR039282A1 (es) Moduladores de receptores de estrogeno
ATE517871T1 (de) Östrogenrezeptormodulatoren
CN201168071Y (zh) 尺骨冠状突假体
AU1855201A (en) 18-nor-steroids as selectively active estrogens
WO2008100560A3 (en) Estrogen receptor modulators, associated pharmaceutical compositions and methods of use
WO2010023512A8 (en) Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them
WO2002053522A3 (en) Novel estrogen receptor ligands and methods i
WO2004073610A3 (en) Estrogen receptor modulators
Nemoto et al. A case of radial nerve paralysis associated with lateral humeral condyle fracture in a child
WO2004026887A3 (en) Estrogen receptor modulators
Pillai et al. Plastibell circumcision supported by a calcium-alginate fibre dressing to reduce bleeding
DOP2002000384A (es) Moduladores de receptores estrogenicos.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]